Mesenchymal stromal cells and chronic inflammatory bowel disease

Algeri, Mattia; Conforti, Antonella; Pitisci, Angela; Starc, Nadia; Tomao, Luigi; Bernardo, Maria Ester; Locatelli, Franco

doi:10.1016/j.imlet.2015.06.018

Cited by 18 publications

(18 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSC are considered a promising medical alternative for treatment of various inflammatory and autoimmune diseases since they have been shown to have the capability of targeting injured tissues and secreting paracrine factors for anti-inflammation [ 34 ]. Although well-known MSC isolated from bone marrow and adipose tissues have been tested to treat colitis due to their anti-inflammatory properties, a highly invasive procedure is required to obtain cells from adult donors.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis

Song

Lee

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

The therapeutic potential of tonsil-derived mesenchymal stem cells (TMSC) prepared from human tonsillar tissue has been studied in animal models for several diseases such as hepatic injury, hypoparathyroidism, diabetes and muscle dystrophy. In this study, we examined the therapeutic effects of TMSC in a dextran sulfate sodium (DSS)-induced colitis model. TMSC were injected in DSS-induced colitis mice via intraperitoneal injection twice (TMSC[x2]) or four times (TMSC[x4]). Control mice were injected with either phosphate-buffered saline or human embryonic kidney 293 cells. Body weight, stool condition and disease activity index (DAI) were examined daily. Colon length, histologic grading, and mRNA expression of pro-inflammatory cytokines, interleukin 1β (IL-1β), IL-6, IL-17 and tumor necrosis factor α, and anti-inflammatory cytokines, IL-10, IL-11 and IL-13, were also measured. Our results showed a significant improvement in survival rates and body weight gain in colitis mice injected with TMSC[x2] or TMSC[x4]. Injection with TMSC also significantly decreased DAI scores throughout the experimental period; at the end of experiment, almost complete reversal of DAI scores to normal was found in colitis mice treated with TMSC[x4]. Colon length was also significantly recovered in colitis mice treated with TMSC[x4]. However, histopathological alterations induced by DSS treatment were not apparently improved by injection with TMSC. Finally, treatment with TMSC[x4] significantly reversed the mRNA levels of IL-1β and IL-6, although expression of all pro-inflammatory cytokines tested was induced in colitis mice. Under our experimental conditions, however, no apparent alterations in the mRNA levels of all the anti-inflammatory cytokines tested were found. In conclusion, our findings demonstrate that multiple injections with TMSC produced a therapeutic effect in a mouse model of DSS-induced colitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis

Song

Lee

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Also, the use of autologous vs . allogeneic MSC is still controversial with no univocal data on the immunological properties of MSCs derived from patients suffering from autoimmune disorders compared to healthy donors [76, 77]. We provide a brief overview of clinical trials performed or ongoing in the setting of immune-related disorders.…”

Section: Clinical Applications Of Mscs In Diseases Mediated By Immmentioning

confidence: 99%

Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Guerrouahen

Sidahmed

Sulaiti

et al. 2019

Stem Cells International

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs), formerly known as mesenchymal stem cells, are nonhematopoietic multipotent cells and are emerging worldwide as the most clinically used and promising source for allogeneic cell therapy. MSCs, initially obtained from bone marrow, can be derived from several other tissues, such as adipose tissue, placenta, and umbilical cord. Diversity in tissue sourcing and manufacturing procedures has significant effects on MSC products. However, in 2006, a minimal set of standard criteria has been issued by the International Society of Cellular Therapy for defining derived MSCs. These include adherence to plastic in conventional culture conditions, particular phenotype, and multilineage differentiation capacity in vitro. Moreover, MSCs have trophic capabilities, a high in vitro self-renewal ability, and immunomodulatory characteristics. Thus, immunosuppressive treatment with MSCs has been proposed as a potential therapeutic alternative for conditions in which the immune system cells influence outcomes, such as inflammatory and autoimmune diseases. The precise mechanism by which MSCs affect functions of most immune effector cells is not completely understood but involves direct contact with immune cells, soluble mediators, and local microenvironmental factors. Recently, it has been shown that their homeostatic resting state requires activation, which can be achieved in vitro with various cytokines, including interferon-γ. In the present review, we focus on the suppressive effect that MSCs exert on the immune system and highlight the significance of in vitro preconditioning and its use in preclinical studies. We discuss the clinical aspects of using MSCs as an immunomodulatory treatment. Finally, we comment on the risk of interfering with the immune system in regard to cancer formation and development.

show abstract

“…MSCs have been shown to enhance anti-inflammatory IL-4 production by Th2 cells, supposedly via a PGE2 ( 48 ). In inflammatory diseases that are associated with high amounts of Th2 cells (e.g., allergies, asthma, Crohn’s disease), MSCs were able to ameliorate disease activity by inhibiting the cytokine production of Th2 cells (IL-4 and IL-5) and increase Th1-derived cytokines (IFN-γ and IL-2) ( 51 , 58 ).…”

Section: Effects On T Cellsmentioning

confidence: 99%

Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells

2015

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSC) have gained immense attraction in regenerative medicine, tissue engineering, and immunotherapy. This is based on their differentiation potential and the supply of pro-regenerative and immunomodulatory signals. MSC can be isolated from a multitude of tissue sources, but mainly bone marrow, adipose tissue, and birth-associated tissues (e.g., umbilical cord, cord blood, placenta) appear to be relevant for clinical translation in immune-mediated disorders. However, only a few studies directly compared the immunomodulatory potency of MSC from different tissue sources. This review compiles the current literature regarding the similarities and differences between these three sources for MSCs with a special focus on their immunomodulatory effects on T-lymphocyte subsets and monocytes, macrophages, and dendritic cells.

show abstract

Mesenchymal stromal cells and chronic inflammatory bowel disease

Cited by 18 publications

References 113 publications

Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis

Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis

Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells

Contact Info

Product

Resources

About